Form 4: Celldex CCO Granted 100,000 Stock Options

Celldex Therapeutics' SVP & Chief Commercial Officer, Teri L Lawver, was granted 100,000 incentive stock options with an exercise price of $22.67.

Summary

• Teri L Lawver, SVP & Chief Commercial Officer of Celldex Therapeutics, Inc. (CLDX), was granted 100,000 Incentive Stock Options (ISOs).
• The transaction date for this grant was November 10, 2025.
• The exercise price for these options is $22.67 per share.
• The options were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
• The options begin vesting on November 10, 2026, with 25% vesting on this date.
• The remaining 75% of the options will vest quarterly in equal amounts over the subsequent 12 quarters.
• The expiration date for these options is November 10, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management retention and alignment with shareholder interests, without any immediate negative implications disclosed in this filing.

Positives

• The grant of 100,000 incentive stock options to a key executive aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The options were granted under an existing and approved 2021 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The vesting schedule for the granted options extends over several years, indicating a long-term incentive for the SVP & Chief Commercial Officer, Teri L Lawver, to contribute to the company's sustained growth and performance.

Industry Context

The grant of stock options to key executives is a standard practice in the biotechnology and pharmaceutical industries, serving as a common mechanism for executive compensation, retention, and alignment of management interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a prevalent form of executive compensation across the biotech and pharmaceutical sectors, aligning executive incentives with long-term company performance.
• The specific terms, such as the exercise price of $22.67 and a 10-year expiration, are within typical ranges for such grants, though a detailed comparison would require examining peer company compensation packages and performance metrics.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the interests of the SVP & Chief Commercial Officer with shareholders, potentially leading to enhanced long-term value creation.
• Employees: This grant is part of the company's overall compensation strategy, which can influence employee morale and retention, particularly for key executives.

Next Steps

• The options will vest according to the specified schedule, with the first 25% vesting on November 10, 2026, and the remainder vesting quarterly over the subsequent 12 quarters.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Stock Options, Incentive Stock Option, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Biotech